Last edition
News about "BESREMi "
US FDA Approves Treatment for Essential Thrombocythemia
The US Food and Drug Administration (FDA) approves Besremi (ropeginterferon alfa-2b-njft) for adults with essential thrombocythemia, with a recommended starting dose of 250 mcg.
Besremi | 02/09/2026 | By News Bureau
PharmaEssentia Secures Taiwan Approval for BESREMi in Essential Thrombocythemia
PharmaEssentia has received Taiwan approval for BESREMi as the first globally approved treatment for Essential Thrombocythemia (ET), marking the first new approved therapy for the disease in nearly 30 years.
BESREMi | 11/06/2026 | By News Bureau | 286
Pint Pharma Gets ANVISA Approval of BESREMi for Polycythemia Vera
Polycythemia Vera (PV) is a rare, chronic, debilitating, and potentially fatal myeloproliferative neoplasm, originating from a disease-initiating stem cell in the bone marrow.
BESREMi | 21/03/2025 | By Aishwarya | 626
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy